Control Bionics Limited engages in the research, development, commercialization, and sale of assistive communications technology systems that allows user with speech and movement disabilities in Australia and North America.
Control Bionics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.56|
|52 Week High||AU$0.52|
|52 Week Low||AU$1.24|
|1 Month Change||-8.20%|
|3 Month Change||-11.11%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-52.54%|
Recent News & Updates
We're Hopeful That Control Bionics (ASX:CBL) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|CBL||AU Medical Equipment||AU Market|
Return vs Industry: Insufficient data to determine how CBL performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how CBL performed against the Australian Market.
Stable Share Price: CBL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CBL's weekly volatility (8%) has been stable over the past year.
About the Company
Control Bionics Limited engages in the research, development, commercialization, and sale of assistive communications technology systems that allows user with speech and movement disabilities in Australia and North America. It offers NeuroNode Trilogy, a wearable device solution for those living with paralysis and loss of speech; NeuroNode3, a wearable EMG control device; and Control Bionics CCS that allow users to communicate with friends and family, send and receive emails and text messages, browse the web, watch videos and movies, read the news, play games, control their home environmental control systems, and others. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020.
Control Bionics Fundamentals Summary
|CBL fundamental statistics|
Is CBL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CBL income statement (TTM)|
|Cost of Revenue||AU$1.43m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.043|
|Net Profit Margin||-86.85%|
How did CBL perform over the long term?See historical performance and comparison
Is Control Bionics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CBL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CBL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CBL is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: CBL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CBL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CBL is good value based on its PB Ratio (2.7x) compared to the AU Medical Equipment industry average (4.5x).
How is Control Bionics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CBL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CBL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CBL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CBL's revenue (34.7% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: CBL's revenue (34.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CBL is forecast to be unprofitable in 3 years.
How has Control Bionics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CBL is currently unprofitable.
Growing Profit Margin: CBL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CBL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CBL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: CBL has a negative Return on Equity (-20.69%), as it is currently unprofitable.
How is Control Bionics's financial position?
Financial Position Analysis
Short Term Liabilities: CBL's short term assets (A$13.7M) exceed its short term liabilities (A$1.2M).
Long Term Liabilities: CBL's short term assets (A$13.7M) exceed its long term liabilities (A$16.9K).
Debt to Equity History and Analysis
Debt Level: CBL is debt free.
Reducing Debt: CBL had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CBL has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 40.9% each year.
What is Control Bionics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Robert William Wong, also known as Rob, serves as the Chief Executive Officer and Board Member at Control Bionics Limited. He joined Control Bionics in early 2017 and he has led the way in developing t...
Experienced Management: CBL's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CBL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: CBL only recently listed within the past 12 months.
Control Bionics Limited's employee growth, exchange listings and data sources
- Name: Control Bionics Limited
- Ticker: CBL
- Exchange: ASX
- Founded: 2005
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$50.127m
- Shares outstanding: 83.55m
- Website: https://www.controlbionics.com
- Control Bionics Limited
- 171 Union Road
- Suite G.03
- Surrey Hills
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:02|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.